1. Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience After FDA Approval;Geyer;Blood,2012
2. FDA. U.S. Food & Drug Administration (2023, October 07). FDA Approves Treatment for Patients with Rare Bone Marrow Disorder, Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder.
3. (2023, October 07). Jakavi (ruxolitinib) Tablets [Highlights of Prescribing Information]. Wilmington, DE: Incyte Corporation, Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf.
4. FDA. U.S. Food & Drug Administration (2023, October 07). FDA Approves Ruxolitinib for Acute Graft-Versus-Host Disease, Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-acute-graft-versus-host-disease.
5. FDA. U.S. Food & Drug Administration (2023, October 07). FDA Approves Ruxolitinib for Chronic Graft-Versus-Host Disease, Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-chronic-graft-versus-host-disease#:~:text=On%20September%2022%2C%202021%2C%20the,patients%2012%20years%20and%20older.